New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 7, 2013
07:11 EDTMACKMerrimack pushes back top line data for NAPOLI-1 to Q2 of 2014
Merrimack now expects to report top line data for NAPOLI-1, its Phase 3 clinical trial of MM-398 in advanced pancreatic cancer, in Q2 of 2014. Merrimack previously disclosed that top line data was expected in Q4 of 2013 or Q1 of 2014. This change is based on a blinded assessment of overall survival events across the entire trial, which are occurring later than forecasted. As previously disclosed, Merrimack met its enrollment target for the trial in August 2013.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:09 EDTMACKMerrimack presents additional Phase 2 biomarker data for MM-121
Subscribe for More Information
September 26, 2014
10:10 EDTMACKMerrimack management to meet with Brean Capital
Subscribe for More Information
05:40 EDTMACKPharmaEngine, Merrimack Pharmaceuticals amend MM-398 license agreement
Subscribe for More Information
September 24, 2014
09:05 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
07:39 EDTMACKMerrimack to hold a conference call
Conference call to discuss the exclusive license and collaboration agreement with Baxter International for the development and commercialization of MM-398 also known as "nal-IRI" will be held on September 24 at 8:30 am. Webcast Link
07:06 EDTMACKBaxter, Merrimack enter exclusive ex-U.S. licensing deal for MM-398
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use